praziquantel has been researched along with Adverse Drug Event in 16 studies
azinox: Russian drug
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this double-blind, placebo-controlled, phase 3 trial, patients with viable intraparenchymal neurocysticercosis were randomly assigned to receive 10 days of combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day), standard albendazole (15 mg/kg per day), or increased dose albendazole (22·5 mg/kg per day)." | 9.19 | Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. ( Bustos, JA; Escalante, D; Garcia, HH; Gavidia, M; Gonzales, I; Lescano, AG; Najar, E; Pretell, EJ; Rodriguez, L; Saavedra, H; Umeres, H; Zimic, M, 2014) |
| "In this double-blind, placebo-controlled, phase 3 trial, patients with viable intraparenchymal neurocysticercosis were randomly assigned to receive 10 days of combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day), standard albendazole (15 mg/kg per day), or increased dose albendazole (22·5 mg/kg per day)." | 5.19 | Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. ( Bustos, JA; Escalante, D; Garcia, HH; Gavidia, M; Gonzales, I; Lescano, AG; Najar, E; Pretell, EJ; Rodriguez, L; Saavedra, H; Umeres, H; Zimic, M, 2014) |
| " The search targeted journals that described the treatment of schistosomiasis in children 5 years and below using praziquantel." | 4.12 | Patient journey and resources mapping to implement a praziquantel mass drug administration program for children aged 5 years and below in resource-limited settings. ( Chimbari, MJ; Kabuyaya, M; Ncube, MV, 2022) |
| "Tribendimidine has a slightly lower cure rate than praziquantel and non-inferiority was not shown." | 2.87 | Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial. ( Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2018) |
| " For the majority of the patients, the drug was well tolerated and no serious adverse events were noted; however, clinical signs in the form of abdominal pain associated or not with diarrhea and vomiting were noted." | 2.78 | [Comparison of the efficacy and safety of praziquantel administered in single dose of 40 versus 60 mg/kg for treating urinary schistosomiasis in Mauritania]. ( Chitsulo, L; Konaté, L; Mamadou, D; Ouldabdallahi, M; Ouldbezeid, M; Ousmane, B, 2013) |
| "Tribendimidine has an efficacy comparable to praziquantel in the treatment of C." | 2.78 | Efficacy and safety of tribendimidine against Clonorchis sinensis. ( Jiang, ZH; Keiser, J; Li, W; Liang, H; Qian, MB; Tan, YG; Utzinger, J; Yang, YC; Yap, P; Zhou, H; Zhou, XN, 2013) |
| " Separately, a previously tested side-effect questionnaire was employed before and 24 hours after PZQ treatment to assess incidence and amelioration of symptoms in young children and their mothers." | 2.77 | Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. ( Arinaitwe, M; Atuhaire, A; Betson, M; Bickle, Q; Kabatereine, NB; Navaratnam, AM; Sousa-Figueiredo, JC; Stothard, JR, 2012) |
| " Age, underweight, and double dosing were associated with increase in ADE incidence, while gender and food intake were not associated with increase in ADE incidence." | 1.72 | Adverse drug effects among students following mass de-worming exercise involving administration of Praziquantel and Albendazole in KEEA Municipality, Ghana. ( Akrasi, W; Boye, A; Brah, AS; Essuman, MA; Osei, V, 2022) |
| " Adverse events were assessed 24 hours post-treatment through questionnaires administered to the parents or guardians." | 1.48 | Safety, efficacy and acceptability of praziquantel in the treatment of Schistosoma haematobium in pre-school children of Kwale County, Kenya. ( Kihara, JH; Kimani, BW; Mbugua, AK; Ng'ang'a, M; Njomo, DW, 2018) |
| " Adverse events were monitored within 4h after dosing by the survey team and 24h after treatment using a questionnaire." | 1.39 | Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. ( Barkiré, N; Djibo, A; Fenwick, A; Garba, A; Gouvras, AN; Labbo, R; Lamine, MS; Sebangou, H; Sofo, B; Utzinger, J; Webster, JP, 2013) |
| " Children remained under medical supervision for 4h and adverse events were recorded." | 1.39 | Safety and efficacy of praziquantel syrup (Epiquantel®) against Schistosoma haematobium and Schistosoma mansoni in preschool-aged children in Niger. ( Alfari, A; Aouami, MA; Djibo, A; Fenwick, A; Garba, A; Lamine, MS; Phillips, AE; Tahirou, A; Utzinger, J, 2013) |
| " Adverse events were assessed and graded 4 and 24 hours posttreatment by interviewing mothers/guardians." | 1.38 | Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. ( Coulibaly, JT; Keiser, J; Knopp, S; N'gbesso, YK; N'Goran, EK; Utzinger, J, 2012) |
| "Praziquantel has been used for the treatment of liver fluke infection, but an oxidative/nitrative stress may occur after a short-term treatment and participate in side effects." | 1.37 | Curcumin induces a nuclear factor-erythroid 2-related factor 2-driven response against oxidative and nitrative stress after praziquantel treatment in liver fluke-infected hamsters. ( Charoensuk, L; Hiraku, Y; Laothong, U; Pinlaor, P; Pinlaor, S; Prakobwong, S; Ruangjirachuporn, W; Yongvanit, P, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Dawson, S | 1 |
| Stahl, S | 1 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Akrasi, W | 1 |
| Brah, AS | 1 |
| Essuman, MA | 1 |
| Osei, V | 1 |
| Boye, A | 1 |
| Ncube, MV | 1 |
| Kabuyaya, M | 1 |
| Chimbari, MJ | 1 |
| Sayasone, S | 1 |
| Keiser, J | 3 |
| Meister, I | 1 |
| Vonghachack, Y | 1 |
| Xayavong, S | 1 |
| Senggnam, K | 1 |
| Phongluxa, K | 1 |
| Hattendorf, J | 1 |
| Odermatt, P | 1 |
| Kimani, BW | 1 |
| Mbugua, AK | 1 |
| Kihara, JH | 1 |
| Ng'ang'a, M | 1 |
| Njomo, DW | 1 |
| Ouldabdallahi, M | 1 |
| Ousmane, B | 1 |
| Ouldbezeid, M | 1 |
| Mamadou, D | 1 |
| Konaté, L | 1 |
| Chitsulo, L | 1 |
| Garcia, HH | 1 |
| Gonzales, I | 1 |
| Lescano, AG | 1 |
| Bustos, JA | 1 |
| Zimic, M | 1 |
| Escalante, D | 1 |
| Saavedra, H | 1 |
| Gavidia, M | 1 |
| Rodriguez, L | 1 |
| Najar, E | 1 |
| Umeres, H | 1 |
| Pretell, EJ | 1 |
| Charoensuk, L | 1 |
| Pinlaor, P | 1 |
| Prakobwong, S | 1 |
| Hiraku, Y | 1 |
| Laothong, U | 1 |
| Ruangjirachuporn, W | 1 |
| Yongvanit, P | 1 |
| Pinlaor, S | 1 |
| Garba, A | 2 |
| Lamine, MS | 2 |
| Barkiré, N | 1 |
| Djibo, A | 2 |
| Sofo, B | 1 |
| Gouvras, AN | 1 |
| Labbo, R | 1 |
| Sebangou, H | 1 |
| Webster, JP | 1 |
| Fenwick, A | 2 |
| Utzinger, J | 4 |
| Sousa-Figueiredo, JC | 1 |
| Betson, M | 1 |
| Atuhaire, A | 1 |
| Arinaitwe, M | 1 |
| Navaratnam, AM | 1 |
| Kabatereine, NB | 1 |
| Bickle, Q | 1 |
| Stothard, JR | 1 |
| Qian, MB | 1 |
| Yap, P | 1 |
| Yang, YC | 1 |
| Liang, H | 1 |
| Jiang, ZH | 1 |
| Li, W | 1 |
| Tan, YG | 1 |
| Zhou, H | 1 |
| Zhou, XN | 1 |
| Coulibaly, JT | 1 |
| N'gbesso, YK | 1 |
| Knopp, S | 1 |
| N'Goran, EK | 1 |
| Tahirou, A | 1 |
| Aouami, MA | 1 |
| Alfari, A | 1 |
| Phillips, AE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical, Laboratory and Imaging Features, Treatment Trends and Long Term Outcomes in Patients With Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study[NCT04706819] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2021-01-15 | Not yet recruiting | |||
| Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole[NCT00441285] | Phase 2/Phase 3 | 156 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of patients whose 6 month MR does not show viable parasites anymore (NCT00441285)
Timeframe: Day 180
| Intervention | participants (Number) |
|---|---|
| Phase III Trial - ABZ+PZQ | 25 |
| Phase III Trial - Increased ABZ | 19 |
| Phase III Trial - Standard ABZ | 15 |
- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on Treatment days 10-11
| Intervention | ng*h/ml (Mean) |
|---|---|
| Albendazole + Praziquantel | 4925.3 |
| Albendazole + Placebo | 2969.6 |
- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose on Treatment day 1
| Intervention | ng*h/mL (Mean) |
|---|---|
| Albendazole + Praziquantel | 1412.2 |
| Albendazole + Placebo | 1111 |
- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on treatment days 10-11
| Intervention | ng*h/ml (Mean) |
|---|---|
| Carbamazepine | 240.2 |
| Phenytoin | 550.1 |
Highest serum level of Albendazole measured from all level assessments in the curve. (NCT00441285)
Timeframe: Treatment day 1 and Treatment days 10-11
| Intervention | ng/mL (Mean) |
|---|---|
| Albendazole + Praziquantel | 1293.9 |
| Albendazole + Placebo | 2232.8 |
- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy. (NCT00441285)
Timeframe: 90 days post tx
| Intervention | Events (Number) |
|---|---|
| Albendazole + Praziquantel | 0 |
| Albendazole + Placebo | 0 |
- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose in treatment day 1
| Intervention | ng*h / mL (Mean) | |
|---|---|---|
| Carbamazepine (n=8) | Phenytoin (n=8) | |
| Albendazole + Praziquantel | 548.3 | 923.7 |
5 trials available for praziquantel and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anthelmintics; Child; Dru | 2018 |
[Comparison of the efficacy and safety of praziquantel administered in single dose of 40 versus 60 mg/kg for treating urinary schistosomiasis in Mauritania].
Topics: Adolescent; Anthelmintics; Body Weight; Child; Dose-Response Relationship, Drug; Drug-Related Side E | 2013 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Double-Blind Method; Drug-Related Side Effects | 2014 |
Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children.
Topics: Animals; Anthelmintics; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Fe | 2012 |
Efficacy and safety of tribendimidine against Clonorchis sinensis.
Topics: Adult; Animals; Anthelmintics; China; Clonorchiasis; Clonorchis sinensis; Drug-Related Side Effects | 2013 |
11 other studies available for praziquantel and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Adverse drug effects among students following mass de-worming exercise involving administration of Praziquantel and Albendazole in KEEA Municipality, Ghana.
Topics: Albendazole; Drug-Related Side Effects and Adverse Reactions; Elephantiasis, Filarial; Female; Ghana | 2022 |
Patient journey and resources mapping to implement a praziquantel mass drug administration program for children aged 5 years and below in resource-limited settings.
Topics: Anthelmintics; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Humans; Mas | 2022 |
Safety, efficacy and acceptability of praziquantel in the treatment of Schistosoma haematobium in pre-school children of Kwale County, Kenya.
Topics: Animals; Anthelmintics; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Fe | 2018 |
Curcumin induces a nuclear factor-erythroid 2-related factor 2-driven response against oxidative and nitrative stress after praziquantel treatment in liver fluke-infected hamsters.
Topics: Animals; Anthelmintics; Anti-Inflammatory Agents, Non-Steroidal; Cricetinae; Curcumin; Drug-Related | 2011 |
Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger.
Topics: Adolescent; Animals; Anthelmintics; Child; Cohort Studies; Drug-Related Side Effects and Adverse Rea | 2013 |
Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium.
Topics: Administration, Oral; Animals; Anthelmintics; Chemoprevention; Child, Preschool; Cote d'Ivoire; Drug | 2012 |
Safety and efficacy of praziquantel syrup (Epiquantel®) against Schistosoma haematobium and Schistosoma mansoni in preschool-aged children in Niger.
Topics: Administration, Oral; Animals; Anthelmintics; Chemoprevention; Child, Preschool; Drug-Related Side E | 2013 |